Evidence-based medicine

ImageBloom Announces Exciting New Partnership With Clinitiative Health Research

Retrieved on: 
Monday, September 25, 2023
Partnership, Evidence-based medicine, Health, Research, Organization, Brand, Patient, ChromeOS, Pharmaceutical industry, Nursing

INDIANAPOLIS, Sept. 25, 2023 /PRNewswire-PRWeb/ -- ImageBloom, a leading provider of healthcare and clinical research marketing solutions, is thrilled to announce its strategic partnership with Clinitiative Health Research, a renowned leader in clinical research innovation. This collaboration marks a significant milestone in both organizations' missions to advance patient-centric healthcare and empower researchers with innovative tools and resources.

Key Points: 
  • ImageBloom, a leading provider of healthcare and clinical research marketing solutions, is thrilled to announce its strategic partnership with Clinitiative Health Research, a renowned leader in clinical research innovation.
  • INDIANAPOLIS, Sept. 25, 2023 /PRNewswire-PRWeb/ -- ImageBloom , a leading provider of healthcare and clinical research marketing solutions, is thrilled to announce its strategic partnership with Clinitiative Health Research , a renowned leader in clinical research innovation.
  • Our collaboration with Clinitiative Health Research is a testament to our commitment to advancing research through strategic partnerships and innovation.
  • This partnership signifies a promising future for healthcare marketing and clinical research, and both ImageBloom and Clinitiative Health Research are eager to embark on this collaborative journey.

Lipogems® Announces 140 independent Peer Reviewed Publications with 5 years of follow up in orthopaedics

Retrieved on: 
Friday, September 22, 2023
Science, Colorectal surgery, General surgery, FDA, Publication, Arthroscopy, Physician, Patient, Evidence-based medicine, Dentistry

ATLANTA, Sept. 22, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.

Key Points: 
  • ATLANTA, Sept. 22, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.
  • "Lipogems has sought out to help patients that have tried conservative options and other therapies with limited relief.
  • "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."
  • "Many physicians have patients that have exhausted other therapies and they don't have many options to help them.

Domo and Regional One Health Named 2023 Nucleus ROI Award Winners

Retrieved on: 
Monday, September 18, 2023
Technology, Nursing, Hospitals, Software, Practice Management, Managed Care, Health, Pharmaceutical, Data Management, Evidence-based medicine, Pharmacy, Patient satisfaction, Catalog, Prescription, MBA, MD, Length of stay, Physician, Patient, ROI, Trauma, SVP, R1 Airlines, Hospital

Domo (Nasdaq: DOMO) announced today that it and Regional One Health , a national leader in healthcare, received a Nucleus Research ROI Award for achieving a total ROI of 190% through the adoption of Domo’s data experience platform.

Key Points: 
  • Domo (Nasdaq: DOMO) announced today that it and Regional One Health , a national leader in healthcare, received a Nucleus Research ROI Award for achieving a total ROI of 190% through the adoption of Domo’s data experience platform.
  • The platform enabled significant improvements in patient care, advanced operational efficiencies and revenue for Regional One Health.
  • As a premier healthcare organization, Regional One Health aims to transform the way it delivers healthcare through informed, data-driven decisions.
  • “We talk a lot about multiplying impact through data and Regional One Health embodies absolutely that in their day to day work,” said Mark Maughan, SVP of customer success at Domo.

Lipogems® Announces 140 independent Peer Reviewed Publications with 5 years of follow up in orthopaedics

Retrieved on: 
Thursday, September 21, 2023
Science, Colorectal surgery, General surgery, FDA, Publication, Arthroscopy, Physician, Patient, Evidence-based medicine, Dentistry

ATLANTA, Sept. 21, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.

Key Points: 
  • ATLANTA, Sept. 21, 2023 /PRNewswire/ -- Lipogems announced today that there are now 140 peer reviewed publications supporting Lipogems' MicroFat with 5 years of follow up in orthopaedics.
  • "Lipogems has sought out to help patients that have tried conservative options and other therapies with limited relief.
  • "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."
  • "Many physicians have patients that have exhausted other therapies and they don't have many options to help them.

Health2047 Backs ScholarRx to Transform Medical Education for the Digital Age

Retrieved on: 
Thursday, September 21, 2023
Tao, Learning, Partnership, Mayo Clinic, Obesity, Evidence-based medicine, EBM, Curriculum, IRO, Privacy, American Medical Association, Medicare, Silicon, Student, Patient, Physician, AMA, Knowledge, Medical device, Nursing, Pharmaceutical industry

MENLO PARK, Calif. , Sept. 21, 2023 /PRNewswire/ -- Health2047, the Silicon Valley-based innovation subsidiary of the American Medical Association (AMA), today introduced ScholarRx as the latest addition to its portfolio of startups reshaping healthcare for a new age. ScholarRx is a curriculum system that modernizes medical education development and delivery via customizable, reusable and interconnectable learning units.

Key Points: 
  • ScholarRx is a curriculum system that modernizes medical education development and delivery via customizable, reusable and interconnectable learning units.
  • Medical knowledge is rapidly expanding and medical schools need help keeping their curriculums up to date.
  • "Health2047 is proud to partner with ScholarRx on its important work in healthcare education innovation," said Lawrence K. Cohen, CEO of Health2047.
  • "We are thrilled to partner with Health2047, as they have become a leader in fostering innovation and collaboration within the healthcare industry," said Dr. Tao Le, chief education officer at ScholarRx.

Global Medical Publishing Market Valued at $9.7 Billion in 2022: Rising Demand for Evidence-Based Medicine Drives Growth

Retrieved on: 
Wednesday, September 6, 2023
Health care, Compound annual growth rate, Conditional sentence, Growth, Cancer, Publishing, Publication, Research, Prevalence, Evidence-based medicine, Physician, Diabetes, Pharmaceutical industry, Medical device

The global medical publishing market achieved a valuation of $9.7 billion in 2022.

Key Points: 
  • The global medical publishing market achieved a valuation of $9.7 billion in 2022.
  • Several key factors are driving this growth, including increased research and development activities, the rising prevalence of chronic diseases, technological advancements, growing demand for evidence-based medicine, globalization of research collaboration, and increased awareness of the importance of publishing medical research.
  • The global burden of chronic diseases like cardiovascular disorders, cancer, and diabetes is a primary driver for medical publishing.
  • The global medical publishing market is segmented by type and product:

A.C. Camargo Cancer Center Harnesses the Power of DoseMe Precision Dosing Platform to Substantially Reduce Toxicity and Kidney Injuries

Retrieved on: 
Wednesday, August 30, 2023
Managed Care, Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Hospitals, Health Technology, Clinical Trials, Science, Health, BCPS, PM, Doctor of Pharmacy, University, Education, Evidence-based medicine, Post, Serum, Acute kidney injury, Survival, Infection, Cancer, International Association, Rehabilitation, Clinical endpoint, Doctor of Philosophy, ECCMID, Vancomycin, Patient, Collection, Nursing, Therapeutic drug monitoring, Diagnosis, Hospital, Yale Cancer Center, TDM, Pharmaceutical industry, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.
  • A.C. Camargo is an integrated Cancer Center for diagnosis, treatment, education and research.
  • Since its inception in 1953, A.C. Camargo has made significant and ongoing contributions to the fight against cancer and it is recognized internationally as a reference institution.
  • "DoseMe is critical to our team's ability to access real-time data and continue to deliver on our promise of customized care for every single patient."

Pacific Dermatology Specialists Announces New Fullerton, CA Location

Retrieved on: 
Friday, August 25, 2023
Salma, Society, Evidence-based medicine, Skin care, PPO, HMO, Dermatology, Baylor University, Multimedia, Human, Medicare, Suite, Patient, Baylor College of Medicine, UCLA, Nursing, Science

FULLERTON, Calif., August 25th, 2023 /PRNewswire-PRWeb/ -- Pacific Dermatology Specialists is proud to announce the opening of our newest location in Fullerton, CA.

Key Points: 
  • Pacific Dermatology Specialists is proud to announce the opening of our newest location in Fullerton, CA.
  • The practice offers a range of skin care services, including medical and pediatric dermatology.
  • FULLERTON, Calif., August 25th, 2023 /PRNewswire-PRWeb/ -- Pacific Dermatology Specialists is proud to announce the opening of our newest location in Fullerton, CA.
  • At Pacific Dermatology Specialists, they understand that receiving timely care is important, which is why they offer same-day and next-day appointments.

Orthobiologics Show Great Promise for Less Invasive Treatment of Certain Musculoskeletal Conditions

Retrieved on: 
Tuesday, August 15, 2023
China Biologic Products, Tissue, Insurance, Osteoarthritis, Tendinopathy, American Academy of Orthopaedic Surgeons, ASC Technology Committee, Evidence-based medicine, Education, Hair, Tennis elbow, Pancreas, Cancer, American Academy, Research, Cell, Platelet-rich plasma, Inflammation, Lupus, FAQ, Elective surgery, Science, Regenerative medicine, Biopharmaceutical, MD, Patient, Physician, PRP, Radio, Liver, AAOS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Rheumatoid arthritis, Pharmaceutical industry, Nursing

ROSEMONT, Ill., Aug. 15, 2023 /PRNewswire/ -- As orthopaedic medicine continues to advance through innovation, research and evidence-based medicine, the complexities and unknowns about newer treatments such as orthobiologics, may leave patients wondering if it is a viable treatment option for them. Orthobiologics, sometimes referred to as regenerative medicine, have shown great promise to treat conditions such as osteoarthritis; however, patients are seeking resources to understand if the treatment is right for them. To educate patients, the American Academy of Orthopaedic Surgeons (AAOS) developed an FAQ published on OrthoInfo.org, that outlines what orthobiologics are and the potential risks and benefits.

Key Points: 
  • Orthobiologics, sometimes referred to as regenerative medicine, have shown great promise to treat conditions such as osteoarthritis; however, patients are seeking resources to understand if the treatment is right for them.
  • To educate patients, the American Academy of Orthopaedic Surgeons (AAOS) developed an FAQ published on OrthoInfo.org , that outlines what orthobiologics are and the potential risks and benefits.
  • The regenerative therapies touted in radio ads or featured on highway billboards may not be grounded in science."
  • Dr. Dragoo recommends patients work with a reputable physician, ideally one who does clinical research in this area and tracks their patient-outcome results.

Dr. Sue Ellen Cox Joins MedSpa Partners

Retrieved on: 
Monday, August 14, 2023
Education, Evidence-based medicine, ASDS, University, MSP, Dermatology, Patient, Health, Society, Nursing, Medical device

TORONTO, Aug. 14, 2023 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Sue Ellen Cox and her team at Aesthetic Solutions to its top-tier North American medical aesthetics platform.

Key Points: 
  • TORONTO, Aug. 14, 2023 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Sue Ellen Cox and her team at Aesthetic Solutions to its top-tier North American medical aesthetics platform.
  • Speaking on her reasons for joining MedSpa Partners, Dr. Cox shared, "I am so proud of everything that we have accomplished at Aesthetic Solutions, and we still have so much opportunity to continue to evolve and grow.
  • MSP CEO Dominic Mazzone commented, "Dr. Sue Ellen Cox is one of the most recognized and respected leaders in the world of medical aesthetics, and has been at the forefront of dermatologic research and education for decades.
  • Dr. Cox and her team are the definition of premier and it's only natural they've found a home with MSP, the premier platform in North America.